Clinical trial NCT00536107: Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Official title: A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Non-Small Cell Lung Cancer
Locally Advanced or Metastatic NSCL Cancer
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-09-27
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, open- label, parallel group, phase IV, multicentre study. The total number of patients expected to be recruited is 40. These randomized patients will have a histologically or cytologically confirmed adenocarcinoma histology of locally advanced or metastatic NSCLC. Patients will be recruited by investigational sites that have expertise in treating patients with non-small cell lung cancer. The study will compare gefitinib monotherapy 250 mg/day orally with docetaxel 60 mg/m2 intravenously over 1 hour every 3 weeks with a primary endpoint of safety and tolerability. The target population will be patients who have received one prior platinum-based chemotherapy and are now considered suitable candidates for further chemotherapy with docetaxel. At study entry, patients will be randomized on a 1:1 basis stratified with respect to performance status (0-1 vs. 2). Patients may continue to receive treatment with either gefitinib or docetaxel until disease progression, unacceptable toxicity or the occurrence of any of the other specific criteria. An independent committee will be appointed to perform a blinded review of all patient scans. Any assessments/visits after screening should be performed within a window of plus or minus 3 working days of the scheduled visit date. If selected screening evaluations are done within 7 days of Day 1, Cycle 1 of treatment, and are acceptable for study entry, they do not have to be repeated on Day 1 unless the investigator believes that they are likely to have significantly changed. Any patient who discontinues from study treatment without radiological evidence of disease progression (except for withdrawal of consent by patient) should continue to have objective tumor assessments every 6 weeks in order to collect information on progression of disease


Eligibility criteria: Inclusion Criteria:

* Locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC, not amenable to curative surgery or radiotherapy
* Treatment with one prior chemotherapy regimen, which must have been platinum based\* \*Patients must have demonstrated radiological or clinical progression since completion of previous chemotherapy regimen.
* Adequate hepatic function, defined as BOTH a bilirubin \< upper limit of reference range (ULRR) AND an "Eligible" combination of transaminases (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) and alkaline phosphatase (ALP) below: Not Eligible: AST or ALT \> 5xULRR, 1.5xULRR \< AST or ALT \< 5xULRR and ALP\> ULRR, 1xULRR \< AST or ALT \< 1.5xULRR and ALP\> 2.5xULRR, AST or ALT \<= ULRR and ALP\> 5xULRR For more information please refer to TAXOTERE® (docetaxel) prescribing information

Exclusion Criteria:

* Prior therapy with gefitinib or other EGFR TK inhibitors (HER-1 receptor inhibitors/small molecule or monoclonal antibody therapy)

  * Prior docetaxel treatment for NSCLC
  * Patients with pre-existing peripheral neuropathy ³ grade 2 (NCI CTCAE criteria)
  * Past medical history of interstitial lung disease, drug induced interstitial disease, radiation pneumonitis that required steroid treatment or any evidence of clinically active interstitial lung disease

Primary outcomes:
measure: Number of Patients With Adverse Event (AE)
timeFrame: From time consent was given to 28 days after last dose of study drug.
measure: Number of Patients With Serious Adverse Events (SAEs)
timeFrame: From time consent was given to 28 days after last dose
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Research Site
Study officials:
affiliation: Director of Chest Department, Chang Gung Memorial Hospital, Linkou
name: Han-Pin Kuo, MD
role: PRINCIPAL_INVESTIGATOR
References: